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Gene editing constitutes a novel approach for precisely correct-
ing disease-causing gene mutations. Frameshift mutations in
COL7A1 causing recessive dystrophic epidermolysis bullosa
are amenable to open reading frame restoration by non-homol-
ogous end joining repair-based approaches. Efﬁcient targeted
deletion of faulty COL7A1 exons in polyclonal patient kerati-
nocytes would enable the translation of this therapeutic strat-
egy to the clinic. In this study, using a dual single-guide RNA
(sgRNA)-guided Cas9 nuclease delivered as a ribonucleopro-
tein complex through electroporation, we have achieved very
efﬁcient targeted deletion of COL7A1 exon 80 in recessive
dystrophic epidermolysis bullosa (RDEB) patient keratinocytes
carrying a highly prevalent frameshift mutation. This ex vivo
non-viral approach rendered a large proportion of corrected
cells producing a functional collagen VII variant. The effective
targeting of the epidermal stem cell population enabled long-
term regeneration of a properly adhesive skin upon grafting
onto immunodeﬁcient mice. A safety assessment by next-gen-
eration sequencing (NGS) analysis of potential off-target sites
did not reveal any unintended nuclease activity. Our strategy
could potentially be extended to a large number of COL7A1
mutation-bearing exons within the long collagenous domain
of this gene, opening the way to precision medicine for RDEB.
INTRODUCTION
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin
fragility genodermatosis caused by loss-of-function mutations in
the COL7A1 gene, encoding type VII collagen (C7). C7 deﬁciency re-
sults in generalized blistering of the skin and other stratiﬁed epithelia,
scarring, ﬁbrosis, mitten-like deformities of hands and feet, and a high
risk of developing metastatic squamous cell carcinoma.1
Ex vivo gene addition therapies based on transplantation of keratino-
cyte sheets modiﬁed by retroviral vectors are already at the clinical
stage for forms of epidermolysis bullosa, including junctional epider-
molysis bullosa (JEB) and RDEB, with encouraging results.2–5 How-
ever, signiﬁcant hurdles face the gene addition approach that include
suboptimal viral gene delivery to the stem cell population, inaccurate
spatial-temporal gene expression, and potential insertional mutagen-
esis-derived adverse events, which are particularly relevant for RDEB
patients given their high proneness to carcinoma development.
Therefore, the implementation of gene therapy approaches for
RDEB based on highly precise gene-editing technologies is warranted
and has been pursued by employing different types of nucleases,
i.e., meganucleases, transcription activator-like effector nucleases
(TALENs), and CRISPR/Cas9, and target cells.6–10
Since neither homology-directed repair (HDR)- nor non-homologous
end joining (NHEJ)-mediated gene-editing strategies tested so far in pa-
tient cells have reached a sufﬁcient level of efﬁcacy to enable therapeutic
C7 replacement by direct transplantation of cells treated in bulk, isola-
tion of corrected cell clones has been necessary, either from patient-
derived induced pluripotent stem cells (iPSCs) and subsequent target
cell derivation6,7 or from patient keratinocytes.9–11 Our laboratory
previously demonstrated long-term skin regeneration from single,
gene-edited epidermal stem cell clones of primary RDEB patient kera-
tinocytes.11 Our original approach involved the use of TALENs deliv-
ered by adenoviral vectors to induce NHEJ-mediated insertions or
deletions (indels) able to restore the reading frameofCOL7A1 in patient
cells carrying the frameshift mutation c.6527insC12 located at exon 80,
which is highly prevalent in the cohort of Spanish RDEB patients.13,14
One of the edited patient keratinocyte clones described in this study
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Figure 1. COL7A1 E80 Dual RNA Guide CRISPR/
Cas9 Deletion Strategy
(A) Scheme of the strategy. Single CRISPR RNA guides
were designed to induce Cas9-mediated DNA double-
strand breaks within selected COL7A1 intron sequences
flanking exon 80 (U-Guides and D-Guides). NHEJ repair
leads to intron-intron rejoining with concomitant E80 dele-
tion and restoration of COL7A1 reading frame and trun-
cated C7 expression. (B) CRISPR guide design. sgRNA
(sgRNAs 1, 2, 3, and 4) sequences and alignment to E80-
flanking sequences E80 are shown. The protospacer
adjacent motif (PAM) is indicated in a darker color. (C)
Predicted amplicon sizes for E80 deletions corresponding
to each sgRNA pair combination. (D) PCR analysis of
genomic DNA from RDEB keratinocytes from patient P1
treated with the RNP complexes containing the different
sgRNA pair combinations. The sg2 + sg3 pair yielded the
highest proportion of excisedE80according to the intensity
of the lower 440-bp band. Deletion ratios assessed by
densitometry are shown in each lane. “A” and “B” refer to
the two different electroporation conditions tested.
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restoration of C7 expression and persistent phenotypic correction
in vivo upon transplantation onto immunocompromised mice.11 The
functionality of C7 variants lacking the amino acids encoded by speciﬁc
exons within the collagenous domain (i.e., exons 73, 80, and 105) has
been previously demonstrated.15,16 Further, Wu et al.17 also showed
thatCol7a1 exon 80-skippedmice generatedwith theCRISPR/Cas9 sys-
temwere indistinguishable from theirwild-type littermates. Building on
these results, we sought more efﬁcient and safe methods to achieve tar-
geted deletion of mutation-carrying COL7A1 exon 80 using the
CRISPR/Cas9 system in RDEB patient keratinocytes.
In this study, we show the remarkable efﬁcacy and safety of a non-viral
strategy employing a dual single-guide RNA (sgRNA)-guided Cas9
nuclease delivered as a ribonucleoprotein (RNP) complex by electro-
poration to precisely excise COL7A1 exon 80 carrying the c.6527insC
mutation in RDEB patient keratinocytes. Moreover, we demonstrate
the long-term skin regeneration ability of the corrected cells upon2 Molecular Therapy Vol. 27 No 5 May 2019grafting of polyclonal and monoclonal popula-
tions of edited cells to immunodeﬁcient mice,
which is indicative of epidermal stem cell correc-
tion. This highly efﬁcacious and one-step strat-
egy would enable quick translation to clinical
application.
RESULTS
Delivery of Dual sgRNA-Guided Cas9
Nuclease to RDEBKeratinocytes as an RNP
Complex Enables Highly Efficient Targeted
Deletion of COL7A1 Exon 80
The dual sgRNA CRISPR/Cas9 deletion strat-
egy of COL7A1 exon 80 (E80) is shown in
the scheme (Figure 1A). Four different sgRNApairs targeted to DNA sequences within introns 79 and 80 were de-
signed (Figure 1B), with the aim of generating deletions of different
sizes covering E80 (Figure 1C). RDEB keratinocytes from a homo-
zygous carrier of the c.6527insC mutation were nucleofected with
the CRISPR/Cas9 RNP complexes at two different electroporation
pulse conditions (designated as A and B, Figure 1D). Once treated,
keratinocytes reached conﬂuency, genomic DNA was extracted, and
E80 deletion (DE80) was assessed by PCR ampliﬁcation of a frag-
ment spanning the sgRNA target sites (Figure 1D). All sgRNA pairs
led to E80 deletion, as shown by the presence of smaller molecular
weight bands with sizes consistent with the distances between Cas9
cutting sites. Electroporation condition B performed better for all
sgRNA pairs. Differences in deletion efﬁcacy were found among
the different sgRNA pairs (i.e., sg2 + sg3 > sg1 + sg3 > sg2 +
sg4 > sg1 + sg4) (Figure 1D). In keratinocytes treated with sg2 +
sg3, the most efﬁcacious pair of guides, E80 deletions accounted
for 66.5% of alleles, as determined by densitometric quantitation
of the PCR products (Figure 1D). The presence of DE80 alleles in
Figure 2. Indel Spectrum in COL7A1 E80 Region
Sequences (Sanger) listed from higher to lower frequencies. 50% of rejoining events corresponded to the fusion between E80-flanking cutting sites plus the addition of a
T (D55 + insT). 95.14% of all alleles had been edited and 84.16% presented E80 deletion.
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Targeted COL7A1 E80 Deletion Produced a Diversity of
Spliceable Chimerical Intronic Variants
A variety of intron 79-intron 80 joining events after Cas9-mediated
cleavage at sequences ﬂanking E80 and subsequent NHEJ repair
were expected to occur in a polyclonal cell population. The character-
ization of the DNA repair outcomes in RDEB keratinocytes from pa-
tient P1 treated with the most effective sgRNA pair (sg2 + sg3) was
initially performed by thymidine-adenine (TA) cloning of PCR prod-
ucts spanning both Cas9 cutting sites and Sanger sequencing of indi-
vidual colonies (n = 82). This analysis detected a spectrum of end
joining repair variants, the majority of which (41 of 82) corresponded
to the fusion of the predicted sgRNA-targeted Cas9 cleavage sites plus
the insertion of a T (Figure 2). Other fusion events included small in-
dels (both deletions and insertions) not affecting intron-splicing sig-
nals and, therefore, not likely to disrupt the splicing of the resulting
chimerical intron. The analysis also showed that, in addition to
dual Cas9 cuts leading to the intended E80 deletion, which accounted
for 84% of alleles, indels corresponding to DNA repair after single
cuts (i.e., at either intron 79 or 80) were also present. Taking these
into account, 95% of alleles had been edited (Figure 2).
Next-Generation Sequencing Analysis of On-Target and Off-
Target CRISPR-Generated Variants
For in-depth characterization of repair events at the on-target region
and to analyze potential off-target cleavage activity at in silico-pre-dicted sites, we performed next-generation sequencing (NGS) of
PCR amplicons spanning the corresponding sites. Genomic DNA
samples from keratinocytes from two homozygous c.6527insC carrier
patients, P1 and P2, treated in duplicate with RNPs (biological repli-
cates BR1 and BR2) as well as control DNA samples from both pa-
tients were subjected to this analysis. On-target NGS analysis
conﬁrmed highly efﬁcient deletion of E80 in Cas9 RNP-treated pa-
tient cells. Sequence variations within a 60-bp window centered on
the midpoint between both cut sites were considered. The two most
frequent repair variants, i.e., fusion of the Cas9 cleavage sites with
(62.2%) or without (9.7%) the insertion of a T (Figure S1), found in
P1 (BR1), were also among the most frequently represented in the
Sanger sequencing characterization (50.0% and 6.1%, respectively)
for this sample (Figure 2). For less frequent repair variants, higher di-
versity was detected with NGS than with Sanger sequencing. Taking
into account all variants resulting in E80 deletion, similar frequencies
of deletion were found with either technique (84% versus 87% for
Sanger and NGS, respectively) in P1 (BR1) patient keratinocytes. Pa-
tient P2 cells, analyzed by NGS only, showed 95% E80 deletion with a
similar spectrum of allelic variants (Figure S1). The lower frequency
of E80 deletion estimated by PCR genotyping in patient P1 (66%),
as compared with Sanger or NGS sequencing estimates, might be ex-
plained by heteroduplex DNA formation between deleted and unde-
leted alleles that results in decreased intensity of the lower molecular
weight PCR band.18
To assess for potential off-target Cas9 cleavage activity, NGS was used
to analyze PCR amplicons covering 278 in silico-predicted sites, whichMolecular Therapy Vol. 27 No 5 May 2019 3
Figure 3. NGS Assessment for the Presence of Indels in Potential Off-Target Sites
PCR amplicons for 244 predicted off-target sites sequenced with at least 1,000 depth, as well as the on-target region, were analyzed (x axis, putative off-target sites
arranged according to the frequency of sequence variation). The 50 highest ranking sites are represented. The first point corresponds to the on-target site (y axis, percentage
of reads containing sequence variations within a 6-bp window centered on the target site for each sgRNA).
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bulges, and the top 53 coding region sites with 4 mismatches for each
guide. After establishing a 1,000-read cutoff for sequencing depth, 244
amplicons were studied. The only sequence variations considered were
indels within a 6-bpwindow centered on the target site for each sgRNA.
The threshold percentage for off-target activity was set at 0.52%, since
this was the highest percentage of indel-containing reads (within the
6-bp window considered for the off-target evaluation) in unedited
control samples. Thus, for each site, indel-containing reads below
this percentage were considered as noise. For every off-target site
analyzed, indel-containing reads represented less than 0.52% of the
total (Figure 3), except for ﬁve predicted sites. Although these sites
showed indel-containing reads at a slightly higher frequency
(0.52%–0.6%) above the 0.52% threshold (Figure S2), the sequence
variations found were also present in both controls and edited sam-
ples, suggesting that these were not bona ﬁde Cas9 off-targets. We
therefore concluded that our NGS analysis of 244 predicted off-target
sites did not reveal any off-target events above the threshold of
detection.4 Molecular Therapy Vol. 27 No 5 May 2019COL7A1 Transcription Analysis after E80 Deletion in c.6527insC
Patient Cells
Our NHEJ correction strategy was designed to generate, upon E80
deletion, new functional introns with donor and acceptor splicing se-
quences corresponding to those from exons 79 and 81, respectively.
Still, the potential generation of cryptic splicing sites could result in
inappropriately spliced transcripts. To conﬁrm proper reading frame
restoration derived from the precise in-frame exon 79-exon 81 junc-
tion, we studied COL7A1 transcription by performing RT-PCR anal-
ysis. For all three sgRNA pairs suitable for E80 deletion, a smaller
band consistent with ampliﬁcation of transcripts lacking E80 was
found (Figure 4A). The intensity of the smaller band (Figure 4A)
was proportional to the efﬁciency of the deletion, as detected by
PCR analysis of genomic DNA (Figure 1D). The RT-PCR products
corresponding to cells treated with the best-performing sgRNA pair
(sg2 + sg3) were TA cloned (n = 49) and Sanger sequenced. This anal-
ysis revealed only two types of transcripts: 47 colonies contained the
proper exon 79-exon 81 junction (96% of transcripts), and 2 colonies
(4%) contained the E80 sequence originating from the unedited
(c.6527insC) allele (Figure 4B).
Figure 4. Collagen VII mRNA Expression of DE80
Gene-Edited RDEB Keratinocytes
(A) RT-PCR analysis ofCOL7A1 transcripts amplified with
primers in exons 78–84. Wild-type/c.6527insC unedited
transcripts produced a 240/241-bp band (non-modified,
n-m) found in all RNA samples. A smaller 205-bp band
corresponding to transcripts lacking exon 80 was de-
tected in samples from edited cells. M, DNA Molecular
Weight Marker IX (Sigma-Aldrich) molecular weight
marker; HK, healthy human keratinocytes; P1, patient
keratinocytes; H2O, negative control without cDNA. (B)
Representative sequence chromatograms showing the
two different resulting transcripts. Transcript frequencies
are shown on the left. (C) COL7A1 expression quantifi-
cation by real-time qPCR using Taqman probes for two
different COL7A1 regions (ex64, specific for all COL7A1
transcripts; and Ex80 probe, for exon 80-containing
transcripts).
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transcripts in gene-edited cells, qRT-PCR was performed using Taq-
man probes speciﬁc for exon 80- and exon 64-encoded sequences.
The exon 64-speciﬁc probe detects transcripts originating from
both edited and unedited alleles, and the exon 80-speciﬁc probe de-
tects only transcription from unedited E80 sequence-containing
alleles. While in healthy donor control keratinocytes both probes de-
tected similar expression levels, in the different RNP-treated pools of
cells we observed higher expression with the exon 64 probe than with
the exon 80 probe. The increased COL7A1 transcription detected with
the exon 64 probe as compared to the exon 80 probe was proportional
to the deletion efﬁcacy of the guide combinations. This analysis was
consistent with the RT-PCR product quantiﬁcation, and it clearly
demonstrated the prevalence of E80-lacking transcripts in edited
cells, conﬁrming sg2 + sg3 guides as the best performing pair for
E80 deletion (Figure 4C).
De Novo C7 Expression after Targeted Deletion of E80 in RDEB
Keratinocytes
COL7A1 reading frame restoration by targeted deletion of mutant
E80 and splicing of the resulting chimerical intron should result in
C7 expression, as we previously observed in a clone of RDEB kerati-
nocytes containing a deletion that encompassed COL7A1 E80
entirely.11 Previous studies from others have also shown that C7-
null cells expressing a retrovirally transferred DE80 COL7A1 cDNA
construct were able to produce a functional C7 variant.16 We there-
fore assessed C7 expression by immunoﬂuorescence and western
blot in RDEB keratinocytes nucleofected with the three most efﬁcient
E80-deleting RNP combinations (sg2 + sg4, sg1 + sg3, and sg2 + sg3).
The number of C7-expressing cells detected by immunoﬂuorescenceanalysis (Figures 5A and S3A) matched the E80
deletion efﬁcacy found by PCR analysis (Fig-
ure 1D) and the COL7A1 mRNA transcription
levels (Figures 4A and 4C). In fact, quantiﬁca-
tion of C7-positive cells by ﬂow cytometry usinga speciﬁc anti-C7 antibody showed that 81% of patient keratinocytes
treated with the sg2 + sg3 RNPs expressed C7 (Figure S3B). Accord-
ingly, western blot analysis performed on cellular extracts further
demonstrated the highest expression of C7 in patient keratinocyte
samples treated with sg2 + sg3 RNPs. The mobility of the C7 band de-
tected in these samples was indistinguishable from that of the wild-
type (WT) protein, as expected since the size difference between
WT C7 and the variant lacking the 12 amino acids encoded by E80
cannot be resolved at the molecular weight range of C7 (290 kDa)
(Figure 5B). In addition, to study C7 secretion, we performed western
blot analysis of proteins precipitated from keratinocyte culture super-
natants. As shown, C7 was present in the media of sg2 + sg3 RNP-
treated keratinocytes (Figure 5C), conﬁrming that removal of E80
does not impair C7 secretion.
Long-Term Engraftment of Polyclonal Populations of DE80
RDEB Keratinocytes
The high proportion of C7-expressing keratinocytes obtained with
the non-viral CRISPR/Cas9 approach indicated that a C7 amount suf-
ﬁcient to restore epidermal-dermal adhesion would be attainable. To
test this, polyclonal populations of edited RDEB cells, obtained with
the different combinations of sgRNAs, and control unedited cells
were used to produce bioengineered skin constructs that were subse-
quently grafted onto immunodeﬁcient mice. Animals weremonitored
for engraftment, and biopsies were obtained at different time points
for histopathological analysis of regenerated skin and assessment of
C7 expression.
Macroscopic examination clearly showed human skin engraftment for
the most efﬁcient guide combination (sg2 + sg3) (Figures 6A and 6B).Molecular Therapy Vol. 27 No 5 May 2019 5
AB C
Figure 5. Collagen VII Expression in DE80 RDEB
Polyclonal Keratinocytes
Keratinocytes were treated with the RNP complex con-
taining different CRISPR dual sgRNA combinations, and
C7 expression was assessed by immunofluorescence (IF)
and western blot. (A) C7 IF analysis. Left top: control,
untreated RDEB (c.6527insC) keratinocytes are shown.
Right top: RDEB keratinocytes were treated with the
sg2 + sg4 pair. Left bottom: RDEB keratinocytes were
treated with the sg1 + sg3 pair. Right bottom: RDEB
keratinocytes were treated with the sg2 + sg3 pair. DAPI
was used to stain nuclei. Scale bars, 50 mm. (B) Western
blot analysis of C7 expression in unedited and edited
RDEB keratinocytes, showing C7 bands intensities
consistent with the IF data. (C) Western blot analysis of
secreted C7 from culture supernatant of normal, un-
treated RDEB and the sg2 + sg3 RNP-treated RDEB
keratinocytes. Protein loading was assessed by Ponceau
red staining of the membrane (bottom). The DE80 C7 in
edited RDEB cells is indistinguishable from that of normal
human keratinocytes.
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showed normal skin architecture and uninterrupted dermal-epidermal
attachment in grafts from these RDEB-edited cells (Figure 6C). On the
contrary, epidermal-dermal separation was evident in grafts from non-
edited cells (Figure 6D). Both types of grafts showed correct suprabasal
human involucrin expression indicating normal epidermal differenti-
ation (Figures 6E and 6F). Immunoperoxidase staining clearly ex-
hibited C7 expression with appropriate localization at the basement
membrane zone (BMZ) exclusively in grafts from edited patient cells
(Figures 6G and 6H). Ultrastructural analysis by electron microscopy
accordingly showed the presence of abundant anchoring ﬁbrils in edi-
ted grafts (Figure 6I), but not in control unedited grafts where dermal-
epidermal separation was evident (Figure 6J).
Patient keratinocytes modiﬁed with the other sgRNA pairs able to
induce alternative E80 deletions, albeit at lower efﬁciencies, were
also tested for skin regeneration. Histological and immunohisto-
chemical analysis 12 weeks after grafting showed full dermal-
epidermal adhesion (Figure S4D) and continuous C7 expression
(Figure S4F) at the BMZ in grafts of keratinocytes edited with sg1 +
sg3. In contrast, microblisters (Figure S4A) and reduced and patchy
C7 expression (Figure S4C) were observed in grafts generated from
cells treated with the less efﬁcient sg2 + sg4 RNP combination, sug-
gesting that the C7 amount provided by these cells was not sufﬁcient
to sustain continuous dermal-epidermal adhesion. Human involucrin
expression demonstrated normal epidermal differentiation of these
grafts (Figures S4B and S4E).6 Molecular Therapy Vol. 27 No 5 May 2019Non-viral CRISPR/Cas9 Delivery Targets
the Epidermal Stem Compartment
The very high efﬁciency of E80 deletion attained
through our non-viral CRISPR/Cas9 RNP com-
plex delivery and the long-term skin regenera-tion achieved with a polyclonal population of corrected cells
suggested that targeting of the epidermal stem cell compartment
had occurred. To conﬁrm this, 11 clones from the bulk RDEB kerati-
nocyte population edited with sg2 + sg3 RNPs were isolated by
limiting dilution. Genotype analysis revealed that all of these clones
had been edited (Figure S5A). Two clones, one monoallelic and the
other biallelic for the E80 deletion (named as DE80/DE80 and
DE80/mut), were selected for in vivo skin regeneration performance.
These clones were accurately genotyped by sequencing (Figure S5C)
and COL7A1 expression was precisely assessed (Figures S5B and
S5D–S5F). Keratinocytes from these clones were labeled with GFP
by lentiviral transduction to facilitate the monitoring of graft persis-
tence over time.
Macroscopic analysis under white and blue (GFP) light illumination
of grafts 20 weeks post-grafting, when several epidermal turnover cy-
cles had occurred, revealed clearly distinguishable human skin
morphological characteristics (Figures 7A and 7B). Grafts from
both clones displayed normal histopathological features with contin-
uous dermal-epidermal attachment (Figures 7C and 7D). As shown
with the polyclonal DE80 RDEB keratinocyte population and consis-
tent with the epidermal-dermal attachment observed histologically,
both C7 expression (Figures 7E and 7F) and anchoring ﬁbrils (Figures
7G and 7H) were also clearly detectable in the monoallelic and bial-
lelic DE80 clonal grafts. Appropriate epidermal differentiation was
conﬁrmed by human involucrin expression immunodetection (Fig-






Figure 6. Skin Regeneration, Collagen VII Expression, and Ultrastructural
Analysis of Grafts from CRISPR/Cas9-Edited (DE80) Polyclonal
Keratinocytes
(A and B) Macroscopic view of engrafted areas 12 weeks after grafting of bio-
engineered skins containing gene-edited (DE80) (A) or unedited RDEB keratino-
cytes (B). (C and D) Histological analysis (H&E staining) of grafts from gene-edited
(DE80) (C) or unedited RDEB keratinocytes (D). The dermal-epidermal separation in
grafts from control, unedited cells is indicated by the red asterisk. (E and F) Human
involucrin (h-inv) immunostaining (suprabasal expression) showing normal
epidermal differentiation in grafts from DE80 keratinocytes (E) or unedited RDEB
keratinocytes (F). (G and H) C7 immunoperoxidase expression analysis showing the
continuous and correct deposition of C7 at the BMZ inDE80-edited grafts (G) and its
complete absence in unedited RDEB keratinocyte grafts (H). Scale bars, 100 mm.
(I and J) Electron microscopy analysis shows the presence of mature anchoring
fibrils (arrows) at the dermal-epidermal junction of the gene-edited RDEB skin (I) and
an empty electron lucent split area, corresponding to a blister (red asterisk) in the
unedited graft (J). Scale bars, 200 nm (I) and 6 mm (J).
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persistent regenerative functionality was maintained19 (Figures S6C
and S6F). Long-term clonal skin regeneration and persistence of the
corrective effect, as determined by this stringent stemness in vivo
test, indicated that the epidermal stem cell compartment had been
effectively targeted.
Blistering Resistance Assay of Gene-Edited Skin Grafts
Mechanical strength of human skin grafts regenerated from patient
P1 cells was assessed by using a suction device able to exert precisely
controlled negative pressure on circular areas of a 3-mm diameter. A
negative pressure of 10 ± 2 kPa20 was applied for 5 min on two
different points of each graft. No blistering was apparent on 12-
week grafts from sg2 + sg3 RNP-treated patient keratinocytes (Figures
8A–8C). Histological analysis showed dermal-epidermal detachment
after suction in grafts from unedited cells (Figure 8D). In contrast, un-
interrupted dermal-epidermal adhesion (Figure 8E) was found after
suction in DE80 grafts. To characterize the basement membrane
integrity upon C7 expression restoration in edited RDEB grafts,
immunoﬂuorescence detection localization of type IV collagen (C4)
and C7 was compared in blisters induced in DE80 RDEB and in
normal human keratinocyte grafts. We found that, in DE80 RDEB
grafts, C4 is localized at the ﬂoor of the blister, indicating that suc-
tion-induced blistering creates a separation between the basal kerati-
nocytes and the lamina lucida, as observed in normal keratinocyte
grafts (Figure S7).
DISCUSSION
To date, more than 650 different mutations causing the different sub-
types of RDEB have been identiﬁed within COL7A1.21,22 Severe
generalized (sev-gen) RDEB, presenting complete absence or marked
deﬁciency of C7, is the most devastating subtype. Mutations leading
to a premature termination codon (PTC), that is, nonsense mutations
or out-of-frame indels, cause sev-gen RDEB. A large proportion of
these mutations occur within the coding region of the C7 collagenous
domain encompassing exons 29–112.23 Although the majority of
COL7A1 mutations are private, a limited number have been shown
to be highly prevalent. This is the case of c.6527insC at E80, which
is characteristic of the Spanish and some Latin American RDEB
cohorts.14,24 To our knowledge, this is the most prevalent COL7A1
mutation. Thus, an advanced gene-editing strategy tailored to this
mutation would be beneﬁcial for a large patient cohort.
All COL7A1 exons coding for the collagenous domain are in frame,
and they might be amenable to an exon-skipping approach aimed
at producing internally truncated, potentially functional C7. How-
ever, most of this domain is constituted by Gly-X-Y repeats that
form the collagen triple helix, and the preservation of this repeat
pattern must be taken into account when considering exon
removal-based corrections. Since deletion of particular exons might
result in structural alterations of C7, the functionality of each variant
derived from exon removal needs to be assessed. Thus, production of
functional C7 able to form anchoring ﬁbrils has been demonstrated





Figure 7. Skin Regeneration, C7 Expression, and
Ultrastructural Analysis of Grafts from CRISPR/
Cas9-Edited (DE80) Stem Cell Clones
Keratinocyte clones, derived from the polyclonal popula-
tion of cells treated with the sg2 + sg3 combination, with
monoallelic (DE80/mut) and biallelic (DE80/DE80) E80
deletions being used to generate bioengineered skin
equivalents and grafted onto immunodeficient mice.
(A and B) Top: macroscopic view of an engrafted mouse
20 weeks after grafting of DE80/mut clone (A) and DE80/
DE80 clone (B). Bottom: close-up view of the grafts under
white and blue (GFP) light show the engrafted areas.
(C and D) Histological analysis (H&E) of regenerated skin
from DE80/mut clone (C) and DE80/DE80 clone (D). Note
the clear dermal-epidermal adhesion in both types of
grafts. (E and F) C7 immunoperoxidase expression anal-
ysis in DE80/mut clone (E) and DE80/DE80 clone (F)
grafts. Both types of grafts display robust and continuous
C7 expression. Insets show C7 expression at the human-
mouse skin boundary. Note that mouse C7 is not
recognized at the dilution of the antibody used. Scale
bars, 100 mm. (G and H) Electron microscopy analysis
shows the presence of well-developed anchoring fibrils
(arrowheads) at the dermal-epidermal junction in grafts
from both types of gene-edited clones. Scale bars,
500 nm.
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oratory using TALE nucleases designed to permanently restore the
COL7A1 reading frame in homozygous c.6527insC carrier keratino-
cytes by NHEJ-mediated repair clearly proved that a deletion encom-
passing the whole of exon 80 restored the COL7A1 reading frame,
resulting in a functional C7 variant10,11 with healthy skin regeneration
capacity. In spite of the increased efﬁcacy with respect to HDR ap-
proaches, COL7A1 frame restoration by NHEJ with TALENs was
only found in approximately 1% of the isolated, expanded, and gen-
otyped epidermal stem cell clones. Although this gene-editing efﬁcacy
was yet not ready for clinical application, this proof-of-principle8 Molecular Therapy Vol. 27 No 5 May 2019correction of primary patient cells by NHEJ,
together with additional previous evidence
from other laboratories showing the function-
ality of DE80 C7,15,16,25,26 led us to seek a
more efﬁcient gene-editing strategy based on
precise targeted excision of E80.
Our non-viral CRISPR/Cas9 delivery protocol
resulted in C7 restoration in a very large per-
centage (close to 85%) of RDEB keratinocytes
without noticeable toxicity, allowing us to over-
come limitations in the use of gene-editing tools
in hard-to-transfect primary cells. CRISPR/
Cas9 RNP delivery systems have previously
been shown to provide fast action and short
permanence in the nucleus, as well as increased
efﬁciency derived from robust nuclease activity,
leading to the introduction of the desired modi-ﬁcation in a high percentage of cells.27–29 This technology therefore
demonstrates a superior safety proﬁle by not using long-lasting
expression from viral vectors (e.g., adenoviral or non-integrative len-
tiviral), which could maintain Cas9 cleavage activity for longer than
desired, thus increasing the probability of off-target indel generation.
Accordingly, assessment of the safety of the strategy by deep
sequencing analysis of a large number of in silico-predicted off-target
sites did not reveal any undesired cleavage. Concurrently, the in-
tended DNA deletion to remove the faulty exon 80 sequence while
preserving appropriate splicing motifs in adjacent introns was ef-
fected in a precise and efﬁcient fashion, as evidenced by the very
A B C
D E
Figure 8. Blister Formation Resistance Assay
(A–C) Macroscopic view of a representative DE80 skin graft regenerated from sg2 + sg3 RNP-treated RDEB (P1) cells before (A), during (B), and after (C) the suction
procedure. Black dotted circle line shows the human skin area where suction was applied. (D and E) Histological (H&E staining) characterization of skin sections corre-
sponding to suctioned areas from unedited (D) and DE80 (E) grafts. Asterisk shows blistered area. Scale bars, 100 mm.
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Gene correction protocols for RDEB cells using CRISPR/Cas9 have
been tried before. Delivery of CRISPR/Cas9 components by plasmid
electroporation into primary ﬁbroblasts7 or by polymer-mediated
transfection of an immortalized keratinocyte cell line9 required
drug or marker selection to achieve mutation correction in a signif-
icant percentage of cells. Wu et al.17 used CRISPR/Cas9 RNPs to
generate an E80-deleted mouse model, proving the functionality
of a C7 variant lacking Col7a1 exon 80. In addition, they explored
the in vivo delivery of CRISPR/Cas9 by direct mouse skin electropo-
ration as a therapeutic avenue, demonstrating that the skin-blis-
tering phenotype was signiﬁcantly ameliorated after treatment.
However, additional experimentation using skin-humanized pre-
clinical models will be necessary before clinical translation of this
approach can be envisioned. Furthermore, even if the challenge of
efﬁcient delivery of CRISPR/Cas9 complexes to human skin is over-
come, preexisting immunity to Cas9 might still pose an additional
hurdle for in vivo therapies.30 Hence, current protocols based on
ex vivo manipulation of epidermal stem cells, already validated in
the clinic, represent a safe and feasible therapeutic scenario.3 How-
ever, gene correction protocols based on CRISPR/Cas9 RNPs deliv-
ered by electroporation to primary patient keratinocytes, the main
source of C7 in the skin, have not been previously reported. Wehave now demonstrated here that one such efﬁcient protocol affords
the possibility of using the whole polyclonal gene-edited keratino-
cyte population capable of producing therapeutic C7 levels, without
the need for drug selection and isolation of corrected clones, which
will facilitate its translation to the clinic. Moreover, we have proven
that functional correction of patient cells has been achieved with
this protocol, not only by histological analysis showing the struc-
tural integrity of the gene-edited skin grafts and ultrastructural anal-
ysis demonstrating the presence of anchoring ﬁbrils at the BMZ but
also by showing resistance to blister formation upon negative pres-
sure application on these grafts.
In the present study, we provide evidence, through a rigorous in vivo
skin regeneration test, that the epidermal stem cell population has
been targeted, providing a long-term effect. A recent study involving
the replacement of a large area of skin affected by JEB showed that
engraftment occurred through a limited number of holoclones not
isolated beforehand.3 Conceivably, a similar clinical outcome could
be anticipated using isolated and characterized bona ﬁde stem cells.
Although the feasibility of epidermal stem clonal-based therapies
with either added or edited genes has been previously established pre-
clinically by us and others11,31–33 and herein accomplished again, in
terms of clinical applicability, the use of the RNP-edited bulk popula-
tion containing long-term corrected stem cells represents a clear prac-
tical advantage.Molecular Therapy Vol. 27 No 5 May 2019 9
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within small and in-frame exons encoding the central helical collag-
enous domain and thus are ideal for an exon-skipping-mediated
approach. Although in this study we have focused on E80 as the
host of a highly recurrent mutation in RDEB patients, our data
provide strong proof of principle for a strategy that should be easily
transferrable to other potentially dispensable exons. Furthermore,
we establish CRISPR/Cas9 delivered as RNP by electroporation
as the state-of-the-art technology for genome editing in primary
keratinocytes.
Overall, our results provide compelling preclinical evidence of the ef-
ﬁcacy and safety of a novel CRISPR/Cas9-based ex vivo polyclonal
gene-editing approach capable of correcting a highly prevalent muta-
tion, opening up the way to feasible gene-editing-based therapy for
RDEB patients that can be easily translated to the clinic.
MATERIALS AND METHODS
Keratinocyte Culture and Isolation of Clones
Patient keratinocytes were originally obtained from skin biopsies of
two RDEB (sev-gen RDEB) patients carrying the c.6527insC homozy-
gous mutation in the COL7A1 gene. Clinical features of these patients
have been previously described (patients 4 and 9).14 Skin biopsies
were obtained from patients after approval from the Ethics Commit-
tee of the collaborating hospital upon informed consent.
Primary human RDEB and healthy donor keratinocytes were
cultured as previously described.11,32 Human primary RDEB kerati-
nocytes from patients P1 and P211 were plated onto lethally irradiated
3T3-J2 cells and cultured in keratinocyte growth complete FAD
(cFAD) medium (KCa), a 3:1 mix of DMEM and Ham’s F12 medium
(Gibco-BRL, Barcelona, Spain) containing fetal bovine calf serum
(Hyclone, GE Healthcare, Logan, UT) (10%), penicillin-streptomycin
(1%), glutamine (2%), insulin (5 mg/mL; Sigma-Aldrich), adenine
(0.18 mmol/L; Sigma-Aldrich), hydrocortisone (0.4 mg/mL; Sigma-
Aldrich), cholera toxin (0.1 nmol/L; Sigma-Aldrich), triiodothyro-
nine (2 nmol/L; Sigma-Aldrich), epidermal growth factor (EGF)
(10 ng/mL; Sigma-Aldrich), and Y-27632 Rho-associated protein ki-
nase (ROCK) inhibitor (Sigma-Aldrich) at 10 mM. To obtain isolated
clones, cells were then trypsinized and plated at low density in
100-mm plates (103cells/plate) with 2  106 lethally irradiated 3T3
feeder cells per plate. Cell clones were then collected using polystyrene
cloning cylinders (Sigma, St. Louis, MO) and expanded for further
analysis. Clonal keratinocytes were GFP labeled using a phosphoglyc-
erate kinase (PGK)-EGFP lentiviral vector, as previously described,34
to allow better visualization and follow-up of regenerated human skin
after grafting.
CRISPR/Cas9 Delivery
sgRNAs were designed using a CRISPR design online tool (https://
zlab.bio/guide-design-resources). Synthetic RNAs and recombinant
Cas9 were purchased from Integrated DNA Technologies (IDT, IL),
and RNP complexes were reconstituted according to the manufac-
turer’s instructions and delivered to the RDEB patient primary kera-10 Molecular Therapy Vol. 27 No 5 May 2019tinocytes by nucleofection using the Neon Transfection System 10 mL
Kit (Thermo Fisher Scientiﬁc). Primary cells were trypsinized and
washed with PBS. 1.5  105 primary keratinocytes were resuspended
in 10 mL Resuspension Buffer R for each reaction, and RNP com-
plexes were added to each sample (72.7 pmol CRISPR RNA
[crRNA][sgRNA]:trans-activating crRNA [tracrRNA], 10.9 pmol
Cas9, 6.6:1 molar ratio). Two electroporation conditions were tested:
1,150 V/30 ms/2 pulses (condition A) and 1,700 V/20 ms/1 pulse
(condition B).35 After electroporation, cells were seeded into 6-well
plates containing a feeder layer and pre-warmed KCa medium.
Genotyping of Gene-Edited Keratinocytes
Genomic DNA was isolated by isopropanol precipitation of keratino-
cyte lysates (lysis buffer was Tris [pH 8] 100 mM, EDTA 5 mM, SDS
0.2%, NaCl 200 mM, and 1 mg/mL proteinase K [Roche Diagnostics,
Mannheim, Germany]) and resuspended in Tris/EDTA (TE) buffer.
Approximately 20–50 ng genomic DNA was used for PCR ampliﬁca-
tion. PCR fragments spanning the nuclease target sites were generated
with primers F1/R (F1, 50-gtgagtggtggctgaagcac-30; and R, 50-accccac
caaggaaactga-30). PCR program TD 68-63 was as follows: 94C for
5 min; 5 cycles of 94C for 30 s, 68C for 30 s, and 72C for 30 s,
decreasing annealing temperature 1C every cycle; followed by 30 cy-
cles of 94C for 30 s, 63C for 30 s, and 72C for 30 s; then 72C for
7 min. PCR products were analyzed in 1.5% agarose gel. Molecular
weight marker was IX (Sigma-Aldrich). For sequencing, PCR prod-
ucts were treated with Illustra ExoProStar (GE Healthcare, UK),
sequenced using Big Dye Terminator version (v.)1.1 Cycle
Sequencing kit (Thermo Fisher Scientiﬁc, Waltham, MA) and exam-
ined on a 3730 DNA Analyzer (Life Technologies, Carlsbad, CA).
Chromatograms were analyzed using Sequencher (Gene Codes,
Ann Harbor, MI) and Chromas (Technelysium, Australia) software.
Bio-Rad Image Lab Software 6.0 was used for PCR band
densitometry.
Genome Editing Off-Target Analysis by NGS
On-target and potential off-target sites were designed, sequenced, and
analyzed using the Thera-Seq genotyping services (Desktop Ge-
netics). Sequencing libraries were prepared and subjected to paired-
end sequencing on a MiSeq using Reagent Kit v.2 (500 cycles)
(Illumina).
COL7A1 Transcription Analysis by RT-PCR and qPCR
Total RNAwas extracted from keratinocytes with the miRNeasy Mini
Kit (QIAGEN, Hilden, Germany), and cDNA was synthesized using
the SuperScript III First-Strand Synthesis System (Invitrogen, Carls-
bad, CA). The primers (forward) 50-aggggtcaggacggcaac-30 and
(reverse) 50-cagctccagtaggtccagtcag-30 were used to amplify 241-bp
(unedited) and 205-bp (exon 80-deleted) fragments spanning exons
78–84 of COL7A1. The PCR program was 94C for 5 min; 5 cycles
of 94C for 30 s, 68C for 30 s, and 72C for 30 s, decreasing annealing
temperature 1C every cycle; followed by 25 cycles of 94C for 30 s,
63C for 30 s, and 72C for 30 s; then 72C for 7 min. The human
glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH) was
analyzed as a loading control with GAPDH- speciﬁc primers
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tgttgctgt-30). For the qPCR analysis, 1:20 dilutions of each cDNA syn-
thesis reaction were analyzed in triplicate using Taqman gene
expression assays Hs00164310_m1 (COL7A1 exon64 probe),
Hs01574801_g1 (COL7A1 exon80 probe), and Hs02758991_g1
(GAPDH probe, control). Ampliﬁcation was performed using a
QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems).
Western Blot Analysis
Keratinocytes were lysed in protein extraction buffer (50 mM Tris-
HCl [pH 7.5], 100 mM NaCl, 1% Nonidet P-40, and 4 mM EDTA)
containing proteinase inhibitors cocktail (Complete Mini, EDTA-
free; Roche Diagnostics, Mannheim, Germany). Lysates were incu-
bated for 30 min on ice and centrifuged at 15,000  g for 30 min at
4C. Supernatants were collected and concentrated by ultraﬁltration
using Amicon Ultra columns (10 kDa; Millipore, Ireland). Protein
concentrations were measured using the Bradford assay (Bio-Rad,
Hercules, CA). For each sample, 40 mg total protein was resolved
on NuPAGE Novex 3%–8% Tris-Acetate gel electrophoresis (Invitro-
gen, Carlsbad, CA) and electrotransferred to nitrocellulose mem-
branes (Invitrogen, Carlsbad, CA). For type VII collagen analysis,
blots were probed with a monospeciﬁc polyclonal anti-C7 antibody
(a generous gift from Dr. A. Nystrom, University of Freiburg). An
antibody against GAPDHwas used as a loading control. Visualization
was performed by incubating with horseradish peroxidase (HRP)-
conjugated anti-rabbit antibody (Amersham, Burlington, MA) and
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL).
Immunofluorescence and Immunohistochemical Staining
For immunoﬂuorescence detection of C7 in keratinocytes, cells grown
on glass coverslips were ﬁxed in methanol/acetone (1:1) for 10 min
at 20C. After washing three times in PBS and once in PBS with
3% BSA (Sigma-Aldrich, St. Louis, MO) for 30 min, cells were incu-
bated with monospeciﬁc polyclonal anti-C7 antibody at 1:5,000 dilu-
tion. Secondary antibody (AlexaFluor488, Invitrogen, Carlsbad, CA)
was used at 1:1,000 dilution. After the ﬁnal washing step in PBS, prep-
arations were mounted using Mowiol (Hoechst, Somerville, NJ)
mounting medium and DAPI 20 mg/mL (Sigma-Aldrich, St Louis,
MO) for nuclei visualization. Immunoperoxidase detection of C7 in
parafﬁn-embedded, formalin-ﬁxed sections was carried out with pro-
teinase K antigen retrieval as described.36 Immunoperoxidase stain-
ing for human involucrin and p63 was performed using rabbit SY5
monoclonal antibody (Sigma) and 4A4 monoclonal antibody, respec-
tively, on parafﬁn sections without antigen retrieval. The ABC perox-
idase kit (Vector Laboratories) was used for immunohistochemical
detection. Immunoﬂuorescence detection of C4 in regenerated skin
tissue was carried out using C4 monoclonal antibody (Clone CIV
22; Dako, M0785). Secondary antibody (AlexaFluor 488, Invitrogen,
Carlsbad, CA) was used at 1:1,000 dilution.
Electron Microscopy
Specimens of approximately 0.4 0.3 cm were ﬁxed for at least 2 h at
room temperature in 3% glutaraldehyde solution in 0.1 M cacodylate
buffer (pH 7.4), cut into pieces of approximately 1 mm3, washed inbuffer, post-ﬁxed for 1 h at 4C in 1% osmium tetroxide, rinsed in wa-
ter, dehydrated through graded ethanol solutions, transferred into
propylene oxide, and embedded in epoxy resin (glycidether 100).
Semi-thin and ultrathin sections were cut with an ultramicrotome
(Reichert Ultracut E). Ultrathin sections were treated with uranyl ac-
etate and lead citrate, and they were examined with an electronmicro-
scope (JEM 1400) equipped with a 2k charge-coupled device (CCD)
camera (TVIPS).
Generation of Skin Equivalents, Grafting onto Immunodeficient
Mice, and Graft Analysis
Animal studies were approved by our institutional animal care and
use committee according to national and European legal regulations.
CRISPR/Cas9 RNP-treated keratinocytes (polyclonal or monoclonal
populations) were seeded on ﬁbrin dermal equivalents containing
RDEB ﬁbroblasts null for C7 expression, prepared as previously
described.37 Bioengineered skin equivalents were grafted onto the
back of 7-week-old female immunodeﬁcient mice (nu/nu, NMRI
background) purchased from Elevage-Janvier (France), as previously
described.32 Grafting was performed under sterile conditions, and
mice were housed in pathogen-free conditions for the duration of
the experiment at the CIEMAT Laboratory Animals Facility (Spanish
registration 28079-21 A). Animals were housed in individually venti-
lated type II cages, with 25 air changes/h and 10 kGy gamma-irradi-
ated soft wood pellets as bedding. All handling was carried out under
sterile conditions, and all experimental procedures were according to
European and Spanish laws and regulations. Grafts were monitored
using a magnifying lens equipped with white and blue light to allow
EGFP visualization. Mice were sacriﬁced at different time points
post-grafting, and grafts were harvested for skin histology, immuno-
histochemistry analyses, and electron microscopy studies.
In Vivo Skin Fragility Test
A suction device developed in our laboratory was set up to exert a
negative pressure of 10 ± 2 kPa on a 3-mm diameter area for 5 min
to induce blister formation onto human skin grafts regenerated in
immunodeﬁcient mice 12 weeks after grafting. Two mice bearing
grafts from unedited and two from sg2 + sg3 RNP-treated keratino-
cytes were used. Suction was applied on two different sites for each
graft. Before applying suction, to promote blister formation, an incan-
descent light bulb was set on top of the graft area approximately 2 cm
away for 2 min.38 After that, the bulb was kept on for the entire dura-
tion of the experiment. The suctioned area was photographed 10 min
after suctioning and excised for histological analysis.
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